Aging and cancer are foci whose solutions are yet to be exhaustively looked into. Many options have been considered so far, and viable options keep coming up especially with the advancement in technology. One of the hypotheses developed is the use of Rapamycin. This is also called Sirolimus or by the trade name, Rapumen. The drug was first formulated in 1972 from a bacterium found in Easter Island. In the beginning, the drug was used as an anti-fungal agent. That was abandoned as soon as it was suspected to have immunosuppressant and antiproliferative properties. Today, it is used to prevent negative response by the body after a transplant. Rapamycin is also common in cancer therapy. Dr. Mikhail Blagosklonny sparked interest in the subject of the role of Target of Rapamycin signaling in aging and cancer. By addressing cellular senescence associated with aging, the drug’s properties may be the find of the decade. Rapamycin was found to rejuvenate immunity. Rapamycin was also proposed in the treatment of Alzheimer’s and muscular dystrophy. Know more about Mikhail at Philly Purge.
Cancer Treatment despite Depth of Pocket
It is undeniable that cancer has become a global menace. Dr. Blagosklonny has conducted extensive research on the prevalence of malignant cells, particularly in advanced age. Many of his papers and lectures have revealed a lot of useful information on cancer, which will be relevant for years to come. The good doctors are on a mission to treat this life-threatening disease efficiently. Most importantly, they are seeking to device a way that is affordable and much less painful to the patient. Mikhail strives to find a way that can aid in eliminating cancerous cells without distorting the healthy cells. Cancer treatment is costly, and for a long time, it has been considered a reserve for the rich. Mikhail foresees a future where it is accessible by all people regardless of their social and financial eminence. Dr. Mikhail is hopeful that his research will be a stepping-stone to innovative cancer therapies in the future. It is Blagosklonny’s fervent hope that his students and next-generation scientists will continue his work. Read Mikhail’s plans for Oncology on Healingmagic.net.
Foundation of Passion
Mikhail Blagosklonny was a professor of Oncology at Roswell Park Cancer Institute in New York up until 2016. He got his MD in Internal Medicine from the First Pavlov State Medical University of St. Petersburg. Dr. Blagasklonny also holds a Ph.D. in Experimental Medicine and Cardiology from the same institution. He was an Associate Professor at New York Medical College in 2002. This was before he left to be a Senior Scientist at Ordway Research Institute until 2009. Dr. Mikhail Blagosklonny is the editor in chief of Aging, Cell Cycle, and Oncotarget.
Shift in Thinking
In a world where cancer and age-related illnesses are paralyzing global citizens, a more proactive startegy needs be taken to find new approaches to treatment and prevention. Dr. Mikhail Blagosklonny’s work has been instrumental in these fields. He is a deservedly revered professional with a legacy that will outlive him.